- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04713592
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects With Moderate to Severe Plaque Psoriasis With Palmoplantar (Non-Pustular) Involvement (PPPsO)
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis with palmoplantar involvement and to assess change in disease symptoms.
Risankizumab is an approved drug for the treatment of psoriasis. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo in Period A. In Period B, all the participants will receive risankizumab. Around 168 adult participants with a moderate to severe plaque psoriasis will be enrolled in approximately 55 sites across the world.
Participants will receive single subcutaneous (administered under the skin) risankizumab or placebo in period A (16 weeks). In period B (36 weeks), all participants will receive subcutaneous risankizumab once every 12 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3E 0B2
- Beacon Dermatology Inc /ID# 220940
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Dr. Chih-ho Hong Medical Inc. /ID# 220941
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Dr. Irina Turchin PC Inc. /ID# 220938
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1C 2H5
- NewLab Clinical Research Inc. /ID# 220934
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y 5G8
- Dr. S.K. Siddha Medicine Professional Corporation /ID# 220936
-
Toronto, Ontario, Canada, M4W 2N4
- Research Toronto /ID# 220939
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 2V1
- Innovaderm Research Inc. /ID# 222126
-
Québec, Quebec, Canada, G1V 4X7
- Centre de Recherche dermatologique du Quebec Metropolitain /ID# 220935
-
-
-
-
-
Caguas, Puerto Rico, 00727
- Dr. Samuel Sanchez PSC /ID# 218789
-
Carolina, Puerto Rico, 00985
- Cruz-Santana, Carolina, PR /ID# 218790
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC /ID# 218788
-
San Juan, Puerto Rico, 00909
- Clinical Research Puerto Rico /ID# 218787
-
San Juan, Puerto Rico, 00909
- GCM Medical Group, PSC /ID# 218786
-
-
-
-
-
Madrid, Spain, 28006
- Hospital Universitario de la Princesa /ID# 224911
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal /ID# 220908
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio /ID# 220907
-
Valencia, Spain, 46014
- Hospital General Universitario de Valencia /ID# 220898
-
Valencia, Spain, 46026
- Hospital Universitario y Politecnico La Fe /ID# 220903
-
Zaragoza, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa /ID# 222492
-
-
Malaga
-
Málaga, Malaga, Spain, 29010
- Hospital Regional de Malaga /ID# 220900
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
- Hospital Universitario Basurto /ID# 220904
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- Advanced Research Associates - Glendale /ID# 219197
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913-6404
- Burke Pharmaceutical Research /ID# 223349
-
Rogers, Arkansas, United States, 72758
- NW Arkansas Clinical Trials Center /ID# 231602
-
-
California
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates /ID# 219195
-
Sacramento, California, United States, 95815
- Integrative Skin Science and Research /ID# 219216
-
San Diego, California, United States, 92103
- Medderm Associates /ID# 219210
-
-
Colorado
-
Centennial, Colorado, United States, 80111-1724
- Colorado Center for Dermatology, PLLC /ID# 219223
-
-
Florida
-
Hollywood, Florida, United States, 33021-6748
- Skin Care Research - Hollywood /ID# 219184
-
Margate, Florida, United States, 33063
- GSI Clinical Research, LLC /ID# 219175
-
Miami Lakes, Florida, United States, 33014-2490
- Savin Medical Group, LLC /ID# 227754
-
Sweetwater, Florida, United States, 33172
- Lenus Research & Medical Group /ID# 219202
-
-
Georgia
-
Alpharetta, Georgia, United States, 30022
- Hamilton Research, LLC /ID# 219224
-
-
Illinois
-
Rolling Meadows, Illinois, United States, 60008
- Arlington Dermatology /ID# 219211
-
Skokie, Illinois, United States, 60077
- Northshore University Health System Dermatology Clinical Trials Unit /ID# 219220
-
-
Indiana
-
Indianapolis, Indiana, United States, 46256
- Dawes Fretzin, LLC /ID# 219219
-
New Albany, Indiana, United States, 47150
- The Dermatology Center PSC - New Albany /ID# 219183
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- Epiphany Dermatology of Kansas LLC /ID# 219208
-
-
Massachusetts
-
Methuen, Massachusetts, United States, 01844-5864
- Allcutis Research LLC /ID# 222272
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- David Fivenson, MD, PLC /ID# 219180
-
Detroit, Michigan, United States, 48202-3046
- Henry Ford Medical Center /ID# 219205
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144-1105
- Advanced Dermatology of the Midlands /ID# 219207
-
-
New Jersey
-
East Windsor, New Jersey, United States, 08520
- Psoriasis Treatment Center of Central New Jersey /ID# 219201
-
-
New York
-
Kew Gardens, New York, United States, 11415
- Forest Hills Dermatology Group /ID# 219200
-
New York, New York, United States, 10029-6504
- Icahn School of Medicine at Mount Sinai /ID# 219206
-
-
Ohio
-
Columbus, Ohio, United States, 43213-4440
- ClinOhio Research Services /ID# 222298
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15260
- University of Pittsburgh MC /ID# 219203
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886-1617
- Velocity Clinical Research-Providence /ID# 223350
-
-
South Carolina
-
Fountain Inn, South Carolina, United States, 29644-1928
- Palmetto Clinical Trial Services /ID# 222275
-
Fountain Inn, South Carolina, United States, 29644-1928
- Palmetto Clinical Trial Services /ID# 222299
-
-
Tennessee
-
Murfreesboro, Tennessee, United States, 37130-2450
- International Clinical Research - Tennessee LLC /ID# 220930
-
-
Texas
-
Dallas, Texas, United States, 75246
- Menter Dermatology Res Inst /ID# 219161
-
Houston, Texas, United States, 77004-8097
- Center for Clinical Studies - Houston (Binz) /ID# 219221
-
-
Utah
-
Salt Lake City, Utah, United States, 84117-4209
- Advanced Clinical Research - Woseth Dermatology /ID# 224750
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Virginia Clinical Research, Inc. /ID# 219181
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of chronic palmoplantar plaque psoriasis (PPPsO) (with or without psoriatic arthritis) for at least 6 months before Baseline and a Palmoplantar Investigator's Global Assessment (ppIGA) of moderate or severe, at Screening and Baseline.
- Must have at Screening and Baseline a plaque psoriasis (PsO) body surface area (BSA) involvement of greater than or equal to one percent, an Static Physician's Global Assessment (sPGA) score of moderate to severe (greater than or equal to three), a PPASI moderate to severe (greater than or equal to eight), at least one additional PsO plaque outside of the palms and soles.
- Must be a candidate for systemic therapy as assessed by the investigator.
- Previously had inadequately controlled disease by topicals, phototherapy and/or systemic treatments.
Exclusion Criteria:
- History of PsO other than chronic plaque type PsO
- History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.
- Ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with PsO assessments.
- Evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV), Active tuberculosis, Active systemic infection/clinically important infections in the last two weeks prior to Baseline.
- Prior exposure to risankizumab.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Risankizumab
Participants will receive risankizumab for 52 weeks
|
Subcutaneous (SC) Injection
Other Names:
|
Placebo Comparator: Placebo
Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
|
Subcutaneous (SC) Injection
Other Names:
Subcutaneous (SC) Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
Time Frame: Baseline (Week 0) through Week 16
|
The ppIGA is a 5 point score ranging from 0 to 4, based on the investigator's assessment of the average erythema (redness), induration (thickness), and scaling of all palmoplantar (non-pustular) psoriatic lesions.
A lower score indicates lower severity, with 0 being "clear" and 1 being "almost clear."
|
Baseline (Week 0) through Week 16
|
Number of Participants with Adverse Events
Time Frame: Baseline (Week 0) through 20 weeks after last dose of study drug (Up to 60 weeks total)
|
Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 20 weeks after last dose of study drug.
|
Baseline (Week 0) through 20 weeks after last dose of study drug (Up to 60 weeks total)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving >= 75% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75) response
Time Frame: Baseline (Week 0) through Week 16
|
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
|
Baseline (Week 0) through Week 16
|
Percentage of Participants Achieving >= 90% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 90) response
Time Frame: Baseline (Week 0) through Week 16
|
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
|
Baseline (Week 0) through Week 16
|
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of "clear" or "almost clear" (0 or 1) with at least a 2 point reduction from Baseline
Time Frame: Baseline (Week 0) through Week 16
|
sPGA is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
|
Baseline (Week 0) through Week 16
|
Percentage of Participants Achieving 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 100) response
Time Frame: Baseline (Week 0) through Week 16
|
PPASI is a linear combination of percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation with scores ranging from 0 to 72.
|
Baseline (Week 0) through Week 16
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M15-994
- 2020-000581-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Risankizumab
-
Shaare Zedek Medical CenterNot yet recruitingCrohn Disease
-
AbbVieActive, not recruitingCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbVieActive, not recruiting
-
AbbVieCompleted
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
-
AbbViePPDRecruitingPlaque Psoriasis | Crohn Disease | Psoriatic Arthritis | Other Conditions for Which Risankizumab is an FDA-approved TreatmentUnited States
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
-
AbbVieCompletedUlcerative Colitis (UC)United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
-
AbbVieNot yet recruiting
-
AbbVieNo longer availableCrohn's Disease | Ulcerative Colitis (UC)